SCHEMBL4282329

SCHEMBL4282329

O=C(Nc1n[nH]c2c1CN(S(=O)(=O)c1cccc(F)c1)C2)c1ccc(N2CCCC(O)C2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.56
AURKA O14965 8/20 0.46
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
CCNA1 P78396 2/20 0.46
KMT2A Q03164 3/20 0.43
AURKB Q96GD4 5/20 0.42
POLB P06746 1/20 0.42
ALK Q9UM73 2/20 0.41
FLT3 P36888 2/20 0.41
LIMK1 P53667 1/20 0.41
LIMK2 P53671 1/20 0.41
AURKC Q9UQB9 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KIT P10721 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4283250 0.91 IGF1R (0.55) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4283625 0.88 IGF1R (0.62) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4291557 0.86 IGF1R (0.64) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4278087 0.86 IGF1R (0.62) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4283397 0.86 IGF1R (0.63) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4287315 0.85 IGF1R (0.77) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4286487 0.85 IGF1R (0.55) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4287701 0.85 IGF1R (0.61) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4292320 0.83 IGF1R (0.58) IGF1RAURKACCNA2CDK2CCNA1
SCHEMBL4290171 0.83 IGF1R (0.64) IGF1RAURKACCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP claimed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US claimed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 IGF1R 530/4885AURKA 42/4885CCNA2 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.